--- title: 'Want to join TwoStep? at TwoStep Therapeutics' canonical: 'https://feeny.ai/job/want-to-join-twostep-twostep-therapeutics-san-francisco-naddamrxamd1' type: 'job' last_seen: '2026-09-16' --- # Want to join TwoStep? at TwoStep Therapeutics - **Company:** TwoStep Therapeutics - **Location:** San Francisco, CA - **Employment:** full-time - **Posted:** 2024-12-04 - **Last confirmed live:** 2026-09-16 - **Apply:** https://jobs.ashbyhq.com/twosteptx/3be81a40-7544-4fdc-8f52-4ba6f292d059 ## Job description Company Overview TwoStep Therapeutics is a biotechnology company developing a pipeline built around a unique tumor-targeting polyspecific integrin-binding peptide (PIP) that can selectively bind several targets that are highly expressed on solid tumors. This multi-targeting feature enables the agent’s broad applicability to a wide range of tumor types and patient populations, overcoming the limitations of single-antigen targeting approaches. The company has leveraged this technology to create a pipeline of targeted cancer therapies for cytotoxic drug delivery and radioligand therapy. TwoStep Therapeutics was co-founded by CEO, Caitlyn Miller, in collaboration with leading academic entrepreneurs at Stanford University, including Nobel Laureate Carolyn Bertozzi, Jennifer Cochran, and Ronald Levy. Position Overview Don’t see a current opening that aligns with your skills, but still eager to join our team? We encourage you to apply here and include a cover letter outlining the types of roles you’re interested in! If you are passionate about advancing cancer therapies and making a meaningful impact in the field, we would love to hear from you. Apply today and be part of TwoStep Therapeutics, where we work together to shape the future of cancer treatment. ## What We Offer At TwoStep Therapeutics, we envision a future where every cancer patient has access to targeted, safe, and effective therapeutic options. We prioritize a diverse, inclusive work environment that fosters personal and professional growth. Our comprehensive benefits include: - Competitive base salary and equity compensation - Unlimited Paid Time Off (PTO) - Comprehensive medical, dental, and vision benefits for individuals and families - 401(k) plan - Company-paid basic life insurance Job title and compensation are dependent on the candidate’s experience and skillset. ## Equal Opportunity Employer TwoStep Therapeutics is an equal opportunity employer. We prohibit unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, mental/physical disability, medical condition, marital status, veteran status, or any other characteristic protected by law. If you require assistance in submitting an application due to incompatible assistive technology or a disability, please contact us at hiring@twosteptx.com. We are committed to accommodating your needs promptly. ## About TwoStep Therapeutics ## Company Overview - **One-liner**: TwoStep Therapeutics is a biotechnology company developing a versatile tumor-targeting peptide platform (PIP) to deliver a range of therapeutic payloads—from small molecules to radiopharmaceuticals—to virtually any solid tumor. - **Entity Type**: Private (Series A) - **Headquarters**: San Carlos, California, United States - **Founded**: 2024 - **Founders**: Caitlyn Miller (CEO), in collaboration with Carolyn Bertozzi (Nobel Laureate), Jennifer Cochran, and Ronald Levy (Stanford University) ## Core Business - **Primary industry**: Biotechnology / Oncology Therapeutics - **Target customers**: B2B (pharma partnerships, licensing) and ultimately B2C (cancer patients) via drug development - **Mission or purpose**: To expand the reach of targeted cancer therapies by overcoming the limitations of single-antigen targeting, enabling safer, more effective treatment for a wide range of solid tumors. ## Products & Services - **PIP Platform (Polyspecific Integrin-binding Peptide)**: A proprietary, modular, ultra-stable peptide that binds selectively to five tumor-associated integrins (αvβ1, αvβ3, αvβ5, αvβ6, α5β1). Designed for rapid tumor uptake, enhanced penetration, and tunable pharmacokinetics. It is compatible with multiple payload types: - **Small molecule drugs** (e.g., drug conjugates) - **Oligonucleotides and proteins** (e.g., larger biologics) - **Radiopharmaceuticals** (radioligand therapy) - **Lead Tumor-Targeted Drug Conjugate**: First pipeline candidate unveiled in 2025. - **Radiopharmaceutical Program**: Early-stage radioligand therapy program, with a VP of Radiopharmaceutical Clinical Development now aboard. ## Market Standing - **Valuation/Market Cap**: Not publicly disclosed (private company). - **Key Metric**: **Total Funding = $27.6M** (Seed: $6.5M in June 2024 led by 2048 Ventures & NFX; Series A: $21.1M in January 2026). - **Notable Investors/Partners**: NFX, 2048 Ventures, Medical Excellence Capital, GC&H Investments, JLabs (Johnson & Johnson Innovation). Academic founders from Stanford University. - **Growth Signals**: - Selected to join **JLABS** (Johnson & Johnson Innovation) in March 2025. - Presented debut lead drug conjugate and radiopharmaceutical program at a scientific conference in 2025. - Headcount of ~7 employees with +11.1% monthly growth; actively hiring for key leadership roles (CMO, Scientist/Sr Scientist). - Rapid progression from Seed to Series A in under 18 months. ## Competitive Advantages - **Multi-targeting specificity**: PIP binds to five different integrins overexpressed on solid tumors, unlike traditional single-antigen approaches. This enables broader tumor coverage and reduces escape mechanisms. - **Modularity & payload versatility**: The platform can deliver small molecules, oligonucleotides, proteins, and radiopharmaceuticals—creating multiple pipeline opportunities. - **World-class academic pedigree**: Co-founded with Nobel Laureate Carolyn Bertozzi and leading Stanford chemical engineers, providing deep scientific credibility and access to cutting-edge research. - **Tumor-penetrating design**: The small, ultra-stable PIP is engineered for rapid tumor uptake and deep penetration, addressing a key limitation of many antibody-based therapies. ## Strategic Focus - **Advancing the lead drug conjugate** toward clinical development. - **Building the radiopharmaceutical pipeline**, including hiring a VP and CMO to lead translational and early clinical work. - **Expanding the team** across R&D, CMC, and clinical operations. - **Establishing pharma partnerships** and potentially licensing the PIP platform to other therapeutic areas. ## Why Work Here - **Culture**: Early-stage biotech with a highly collaborative, fast-paced environment. The team is small (~7 people), meaning every hire has outsized impact and visibility. - **Remote/Hybrid/Office**: Likely on-site/hybrid given the lab-based nature of the work (headquarters in San Carlos, CA; second office in Palo Alto). - **Notable perks & engineering culture**: Opportunity to work directly with founders and world-renowned academic scientists. Strong focus on scientific innovation and drug development from discovery to clinic. Recent hires include an Executive Assistant, Head of Clinical Operations, and VP of Radiopharmaceutical Development—indicating a growing, professionalizing organization. - **Growth trajectory**: Just raised a $21M Series A; the company is in a high-growth phase with active hiring for senior scientific and clinical roles. ## Sources 1. [twosteptx.com](https://twosteptx.com/) 2. [twosteptx.com - Our Science](https://twosteptx.com/our-science/) 3. [LinkedIn - TwoStep Therapeutics](https://www.linkedin.com/company/twostep-therapeutics) 4. [CB Insights - TwoStep Therapeutics](https://www.cbinsights.com/company/twostep-therapeutics) 5. [Jobs.ashbyhq.com - TwoStep Therapeutics](https://jobs.ashbyhq.com/TwoStepTx)